Brain Metastases in EGFR-mutant NSCLC: Outcome of Osimertinib plus /- Radiation Therapy in a Real-World Canadian Cohort

被引：0
|
作者：
Litt, I. [1 ]
Gibson, A. [2 ]
Dean, M. [2 ]
Elegbede, A. [2 ]
Bebb, G. [2 ]
Cheung, W. [1 ]
Pabani, A. [1 ]
机构：
[1] Alberta Hlth Serv, Calgary, AB, Canada
[2] Univ Calgary, Calgary, AB, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
Non-small cell lung cancer; Targeted Therapies; Brain Metastases;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-07
引用
收藏
页码：S434 / S434
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy of osimertinib plus bevacizumab as first-line treatment in EGFR-mutant NSCLC with brain metastases: A dynamic ctDNA-guided study
    Wei, Fang
    An, Juan
    Hua, Yichun
    Ding, Xiaosheng
    Sun, Shibin
    Li, Xiaoyan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] ERLOTINIB VERSUS RADIATION THERAPY FOR BRAIN METASTASES IN PATIENTS WITH EGFR-MUTANT LUNG ADENOCARCINOMA
    Gerber, Naamit K.
    Yamada, Yoshiya
    Shi, Weiji
    Zhang, Zhigang
    Riely, Gregory
    Beal, Kathryn
    Yu, Helena A.
    Chan, Timothy A.
    Rimner, Andreas
    Wu, Abraham J.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S902 - S902
  • [23] Impact of co-mutations on the prognosis of targeted therapy in EGFR-mutant advanced NSCLC: A result of real-world study
    Pan, S.
    Wang, N.
    Tian, M.
    Song, X.
    ANNALS OF ONCOLOGY, 2023, 34
  • [24] Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Lung Adenocarcinoma
    Gerber, Naamit K.
    Yamada, Yoshiya
    Rimner, Andreas
    Shi, Weiji
    Riely, Gregory J.
    Beal, Kathryn
    Yu, Helena A.
    Chan, Timothy A.
    Zhang, Zhigang
    Wu, Abraham J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 89 (02): : 322 - 329
  • [25] Impact of Co-mutations on the Prognosis of Targeted Therapy in EGFR-Mutant Advanced NSCLC: a Result of Real-World Study
    Pan, S.
    Wang, N.
    Tian, M.
    Song, X.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S330 - S331
  • [26] Efficacy of Osimertinib Continuation Plus Metronomic Oral Vinorelbine for EGFR-mutant Advanced NSCLC Beyond Limited Progression on Osimertinib
    Li, Meifang
    Lin, Cheng
    Lin, Jinghui
    Chen, Shijie
    Weng, Lihong
    He, Zhiyong
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2023, 23 (19) : 2095 - 2101
  • [27] Preclinical Activity of AZD9291 in EGFR-Mutant NSCLC Brain Metastases
    Ballard, Peter
    Yang, Pamela
    Cross, Darren
    Yates, James
    Finlay, M. Raymond V.
    Grist, Matthew
    Box, Matthew
    Johnstrom, Peter
    Varnas, Katerina
    Malmquist, Jonas
    Halldin, Christer
    Farde, Lars
    Thress, Kenneth
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S300 - S300
  • [28] Outcomes Among Patients with EGFR-Mutant Metastatic NSCLC with and without Brain Metastases
    Nadler, E.
    Pavilack, M.
    Espirito, J.
    Baidoo, B.
    Fernandes, A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S383 - S383
  • [29] Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Tozuka, Takehiro
    Noro, Rintaro
    Mizutani, Hideaki
    Kurimoto, Futoshi
    Hakozaki, Taiki
    Hisakane, Kakeru
    Naito, Tomoyuki
    Takahashi, Satoshi
    Taniuchi, Namiko
    Yajima, Chika
    Hosomi, Yukio
    Hirose, Takashi
    Minegishi, Yuji
    Okano, Tetsuya
    Kamio, Koichiro
    Yamaguchi, Tomoyoshi
    Seike, Masahiro
    LUNG CANCER, 2024, 191
  • [30] Osimertinib as a neoadjuvant therapy in resectable EGFR-mutant non-small cell lung cancer: a real-world, multicenter retrospective study
    Li, Jialong
    Wang, Youyu
    Zhao, Zerui
    Wang, Sihua
    Yan, Wanpu
    Chen, Xiaohui
    Chen, Tianxiang
    Li, Pengfei
    Wang, Sheng
    Fang, Qiang
    Peng, Lin
    Han, Yongtao
    Tang, Jian
    Leng, Xuefeng
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (12) : 3344 - 3351
12345